当前位置:首页 > 报告详情

AZ-JPM-2026-Presentation.pdf

上传人: 明**** 编号:1069700 2026-01-17 25页 1.64MB

1、JP Morgan Healthcare ConferenceAradhana Sarin,EVP&CFO13 January 20262Cautionary statements regarding forward-looking statementsIn order,among other things,to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995,AstraZeneca(hereafter the Group)provides the fo

2、llowing cautionary statement:This document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expected revenues,margins,earnings per share or other financial or other measures.Altho

3、ugh the Group believes its expectations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.The forward-lo

4、oking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward-looking statements by using the words anticipates,believes,expects,intends and s

5、imilar expressions in such statements.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,among other things:the risk of failure or delay in delivery of pipeline or launch of

6、new medicines;the risk of failure to meet regulatory or ethical requirements for medicine development or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk of pricing,affordability,access and competitive pressures;the risk of failure to m

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **财务与业绩**:2025年前9个月总收入增长11%至675.2亿美元,核心每股收益增长15%;目标2030年总收入达800亿美元。 2. **管线进展**:2024年以来已有29项III期积极读出,2025年关键III期试验(如SERENA-6、DESTINY-Breast09等)驱动未来增长,潜在风险调整收入超100亿美元。 3. **治疗领域**:肿瘤(43%)、罕见病(16%)、心血管/肾/代谢(23%)、呼吸/免疫(15%)为主要收入来源,美国(43%)和中国(12%)为关键市场。 4. **技术布局**:加速抗体偶联药物(ADC)、细胞疗法、双特异性抗体等创新技术,14项ADC III期试验推进;AI应用缩短研发时间50%。 5. **风险提示**:强调前瞻性陈述不确定性,涉及研发延迟、监管失败、竞争压力等风险。
**2030收入目标?** **ADC药物进展?** **美国市场布局?**
客服
商务合作
小程序
服务号
折叠